ArticleJournal of nanobiotechnology2025
Lipid nanoparticles-mRNA based on the consensus sequences of avian coronavirus S1 and N genes protect animals against multiple viral infections.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Effective Nanoadjuvant System for Poultry Vaccines.Vaccines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Lipid nanoparticles-mRNA play important roles in SARS-CoV-2 infection control. Avian coronavirus infectious bronchitis virus (IBV) comprises eight genotypes with a lack of cross-protection, causing severe economic losses to the poultry industry. Using immunoinformatics methods, five consensus sequence antigens against prevalent IBV strains were designed. Four monovalent lipid nanoparticles-mRNA (GI-19, GI-13, GI-7, GVI-1) and one quadrivalent lipid nanoparticles-mRNA were constructed to develop a broad-spectrum IBV vaccine. The safety and biodistribution of the lipid nanoparticles-mRNA were evaluated in SPF chickens and confirmed that it induced a strong and durable immune response. The lipid nanoparticles-mRNA efficacy in SPF chickens was verified in infection assays with four genotypes of IBV strains, the results showed that immunization with a 10 µg dose provided complete protection for the chickens, while immunization with a 5 µg dose reduced disease severity, organ damage, and mortality, and inhibited viral replication and shedding. Our results indicate that these Lipid nanoparticles-mRNA are immunogenic and protective in preclinical animal models. These data can provide a basis for IBV prevention and control and the development of mRNA vaccines against other prevalent viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.